ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1381

Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis

Cécile Bergua1, Marine Besnard1, Ghenima Ahmil2, Laure-Helene Ouisse2, Nadège Vimond1, Apolline Salama2, Bérangère Evrard2, Elise Brisebard3, Alexis Collette1, Fréderic Blanchard4, Thibault Larcher3, Ronald Van Brempt1, Benoit Le Goff5, Ignacio Anegon2 and Carole Guillonneau1, 1AbolerIS Pharma, Nantes, France, Nantes, France, 2Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, 3APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, 4INSERM UMR1229, Nantes, France, Nantes, France, 5CHU Nantes, France, Nantes, France

Meeting: ACR Convergence 2024

Keywords: B-Lymphocyte, Collagen-Induced Arthritis, immunology, T Cell, Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood B cells and some T cell subsets (Th1 and precursors, TEMRA cells). We demonstrated that administration of an anti-CD45RC mAb in preclinical models of transplant rejection, graft versus host disease (GvHD), Duchene dystrophy or APECED leads to prevention or control of the disease. RA is a chronic relapsing/remitting disease characterized by synovitis, joint deformity, loss of function and increased mortality. While T-cells are a major component in the pathogenesis, B-cells are also pathogenic.

In this study, we deciphered the mechanism of action of the anti-human CD45RC mAb and assessed its effect in vitro and in vivo on human immune cell populations. We then assessed the potential of the anti-CD45RC mAb in an experimental model of rheumatoid arthritis.

Methods: Cells were isolated from peripheral blood. Apoptosis, antibody-Dependent Cellular Cytotoxicity (ADCC), antibody-Dependent Cellular Phagocytosis (ADCP) and Complement-Dependent Cytotoxicity (CDC) were assessed by Annexin V/DAPI staining and cell count. In vivo studies were performed in CD34+ immune-humanized NSG mice, in a model of xenogeneic GVHD in human PBMC-reconstituted immunodeficient NSG mice or in a model of collagen-induced arthritis (CIA) in rat.

Results: We demonstrated that the humanized anti-human CD45RC mAb induced CD45RChigh T and B cell death mainly by direct apoptosis of CD45RChigh cells, inducing signaling but not cytokine release. We demonstrated contribution of cross linking and ADCP. Using in vivo studies in CD34+ immune-humanized NSG mice, we showed that a single iv administration of anti-CD45RC mAb induced an efficient killing of CD45RChigh T and B cells as soon as day 1, this effect was dose and time-dependent and targeted cells recovered by day 24. We also showed a dose dependent efficacy in a model of xenogeneic GVHD in human PBMC-reconstituted immunodeficient NSG mice.

Treatment with an anti-rat CD45RC mAb in a rat model of CIA efficiently prevented the disease, completely inhibited anti-collagen antibody production, inflammation of the paws and GM-CSF secretion in the sera. Efficacy of the anti-CD45RC mAb correlated with depletion of CD45RChigh T and B cells by d3 ( >94%) and until sacrifice with conserved Treg numbers. Analysis of RA patients showed a strong infiltration by CD45RChigh cells of synovial tissues using IHC.

Conclusion: Altogether our study demonstrates the mechanisms by which anti-human CD45RC mAb mediates CD45RChigh T and B cell death to control immune responses and that anti-CD45RC mAb treatment is a potent immunomodulatory agent rebalancing the Treg/teff ratio to reduce joint inflammation and disease activity in RA and a potential alternative for first line DMARD.

Supporting image 1


Disclosures: C. Bergua: None; M. Besnard: None; G. Ahmil: None; L. Ouisse: None; N. Vimond: None; A. Salama: None; B. Evrard: None; E. Brisebard: None; A. Collette: None; F. Blanchard: None; T. Larcher: None; R. Van Brempt: None; B. Le Goff: None; I. Anegon: None; C. Guillonneau: None.

To cite this abstract in AMA style:

Bergua C, Besnard M, Ahmil G, Ouisse L, Vimond N, Salama A, Evrard B, Brisebard E, Collette A, Blanchard F, Larcher T, Van Brempt R, Le Goff B, Anegon I, Guillonneau C. Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/elimination-of-cd45rchigh-t-and-b-cells-by-anti-cd45rc-mab-lead-to-efficient-control-of-experimental-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elimination-of-cd45rchigh-t-and-b-cells-by-anti-cd45rc-mab-lead-to-efficient-control-of-experimental-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology